MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Organon & Co

Fechado

SetorSaúde

14.74 4.39

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.88

Máximo

14.75

Indicadores-chave

By Trading Economics

Rendimento

-250M

109M

Vendas

10M

1.6B

P/E

Médio do Setor

4.357

63.778

EPS

0.9

Rendimento de Dividendos

7.72

Margem de lucro

6.847

Funcionários

10,000

EBITDA

-64M

338M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+28.95% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

7.72%

2.39%

Próximos Ganhos

1 de mai. de 2025

Próxima data de dividendos

12 de jun. de 2025

Próxima data de ex-dividendo

9 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-304M

3.7B

Abertura anterior

10.35

Fecho anterior

14.74

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Organon & Co Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 23:55 UTC

Ações em Alta

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 de abr. de 2025, 22:50 UTC

Grandes Movimentos do Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 de abr. de 2025, 21:08 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 de abr. de 2025, 21:00 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 de abr. de 2025, 23:56 UTC

Conversa de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 de abr. de 2025, 23:44 UTC

Principais Notícias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 de abr. de 2025, 23:10 UTC

Conversa de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:57 UTC

Conversa de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 de abr. de 2025, 22:43 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 de abr. de 2025, 22:12 UTC

Conversa de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 de abr. de 2025, 21:48 UTC

Principais Notícias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 de abr. de 2025, 21:41 UTC

Conversa de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 de abr. de 2025, 21:04 UTC

Principais Notícias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 de abr. de 2025, 21:03 UTC

Conversa de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 de abr. de 2025, 20:53 UTC

Ganhos

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 de abr. de 2025, 20:52 UTC

Ganhos

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparação entre Pares

Variação de preço

Organon & Co Previsão

Preço-alvo

By TipRanks

28.95% parte superior

Previsão para 12 meses

Média 19.2 USD  28.95%

Máximo 24 USD

Mínimo 16 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Organon & Co - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

1

Comprar

3

Manter

2

Vender

Pontuação Técnica

By Trading Central

N/A / 15.77Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.